iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
- Nasdaq ends sharply higher as Alphabet and AMD fuel AI surge
- Broadcom annual guidance falls short after Q4 results beat; hikes dividend
- Stocks could be in 'panic' mode in 2024, warns JPM's Kolanovic
- Lululemon Athletica Q3 results top estimates, but revenue guidance falls short
- Can S&P 500 rally without the Magnificent 7 leading the way? 'Easy' says BofA
BRYAN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, provides the following link to listen virtually to the 2021 Annual Shareholders meeting: www.virtualshareholdermeeting.com/IBIO2021. The meeting will be held at 9:00 AM EST on December 22, 2021.
iBio had partially adjourned the 2021 Annual Stockholder meeting related to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow more shareholders to vote. Previously 64% and 67% of shareholders had voted in favor of these proposals, but more shareholder votes are needed to ratify the proposals.
If you have already voted your shares “FOR” Proposals 4 and 5, you do not need to vote again, and we thank you for your support. If you did not vote at all, abstained from voting for, or voted against with respect to the proposals, we kindly ask you to vote, or to reconsider your vote.
For additional information on the Proposals, please see our Shareholder Vote FAQ.
About iBio, Inc.
iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, antigens, and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.
Stephen Kilmer iBio, Inc. Investor Relations (646) 274-3580 [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanoma Corporation - Managers' Transactions
- Form 8.5 (EPT/RI) - FireAngel Safety Technology Group Plc
- Form 8.5 (EPT/RI) - abrdn European Logistics Income plc
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!